Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa vs Navelbine + Carboplat in EGFR+ NSCLC
NCT03203590Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2017
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03203590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203590.